Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + TKIs + TACE + SBRT for advanced hepatocellular carcinoma with portal vein tumor thrombosis
ChiCTR2400082386Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, sorafenib, donafenib and lenvatinib in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
sintilimabsorafenibdonafeniblenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400082386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082386.